Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

The patents of the Entresto fixed dose combination are set to expire on January 16
Sohini Das Mumbai
2 min read Last Updated : Jan 15 2023 | 9:33 PM IST
In a breather to Indian drug makers, the Delhi High Court has advised the assistant patent controller to hear Hyderabad-based drugmaker Natco Pharma’s opposition to Novartis’ patent for the latter’s blockbuster heart failure drug (a combination of sacubitril and valsartan).

This decision by the court assumes significance because it would likely open the door for Indian pharma players to launch their generic versions of the heart failure drug Vymada (sold globally as Entresto).

The court had on Wednesday reserved the order on Natco Pharma’s writ petition over the grant of a patent to Novartis by the Indian Patent Office (IPO) for its drug Vymada.

Natco had argued before Justice C Hari Shankar (of the Delhi High Court) against the grant of the patent by the IPO to the pharmaceutical composition comprising sacubitril and valsartan as a sodium salt complex of the Vymada.

Had the court upheld Novartis’ latest patent, it could have potentially scuttled the plans of several Indian drug companies to launch their generic versions of this popular cardiac drug.

The patents of the Entresto fixed-dose combination are set to expire on January 16.

Industry sources say now with this order in favour of Natco Pharma, Indian companies may start launching generic versions as early as next week.

Vymada is a fixed-dose combination drug advised to heart-failure patients.

Sacubitril (neprilysin inhibitors) works to control blood volume while valsartan is a common anti-hypertensive. This effect reduces work on the heart and reduces blood pressure. The combined effect of the two medicines reduces the strain of the failing heart.

Several Indian drug firms are in the fray to launch the generic of this heart failure medicine, which has already managed to reach a size of Rs 550 crore in the Indian cardiac market.

Globally, this drug is estimated to have a size of $4 billion.

“The top firms are readying to launch the drug, and price slashes would be in the range of 50-70 per cent immediately,” said an industry source. At present, each Vymada 100mg tablet costs around Rs 85.

Dr Reddy’s Laboratories has armed its arsenal by acquiring the Cidmus brand from Novartis earlier this year for Rs 463 crore.

Trade sources say this is one of the fastest-growing drugs in the Rs 23,000 crore cardiac market in the country.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Natco PharmaNovartisDelhi High CourtPharma

Next Story